A combination drug therapy improves cognition and reverses gene expression changes in a mouse model of Huntington's disease

European Journal of Neuroscience

Volumn 21, Issue 4, 2005, Pages 855-870

  Motion, A Jennifer ^a   Hunt, Mark J ^a   Hodges, Angela K ^b   Lewis, Paul D ^b   Redfern, Armanda J ^b   Dunnett, Stephen B ^a,c   Jones, Lesley ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Creatine; Moclobemide; Morris water maze; Neurodegeneration; R6 2; Tacrine

Indexed keywords

CREATINE; MOCLOBEMIDE; TACRINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOSOMAL DOMINANT DISORDER; COGNITION; CONTROLLED STUDY; DNA MICROARRAY; EXON; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC DISORDER; HUNTINGTON CHOREA; MAZE TEST; MOTOR PERFORMANCE; MOUSE; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYMPTOMATOLOGY; SYNAPTIC TRANSMISSION; TRANSGENIC MOUSE;

AGE FACTORS; ANIMALS; BODY WEIGHT; BRAIN CHEMISTRY; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; GENE EXPRESSION; GLUCOSE; HUNTINGTON DISEASE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOTOR ACTIVITY; NEUROTRANSMITTER AGENTS; NOOTROPIC AGENTS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; ROTAROD PERFORMANCE TEST; SPATIAL BEHAVIOR; TRINUCLEOTIDE REPEATS;

EID: 16244384501     PISSN: 0953816X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1460-9568.2005.03895.x     Document Type: Article

References (55)

1. Alvarez. J.C., Sanceaume, M., Advenier, C. & Spreux-Varoquaux, O. (1999) Differential changes in brain and platelet 5-HT concentrations after steady-state achievement and repeated administration of antidepressant drugs in mice. Eur. Neuropsychopharmacol., 10, 31-36.
2. Amrein, R., Martin, J.R. & Cameron, A.M. (1999) Moclobemide in patients with dementia and depression. Adv. Neurol., 80, 509-519.
3. Andersen, K.E., Louis, E.D., Stern, Y. & Marder, K.S. (2001) Cognitive correlates of obsessive and compulsive symptoms in Huntington's disease. Am. J. Psychiatry, 158, 799-801.
4. Augood, S.J., Faull, R.L. & Emson, P.C. (1997) Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann. Neurol., 42, 215-221.
5. Augood, S.J., Faull, R.L., Love, D.R. & Emson, P.C. (1996) Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington's disease: a detailed cellular in situ hybridization study. Neuroscience, 72, 1023-1036.
6. Ballard, C.G. (2002) Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur. Neurol., 47, 64-70.
7. Bates, G., Harper, P.S. & Jones, L. (2002) Huntington's Disease, 3rd edn. Oxford University Press, Oxford. 556pp.
8. Blalock, E.M., Chen, K.C., Sharrow, K., Herman, J.P., Porter, N.M., Foster, T.C. & Landfield, P. (2003) Gene microarrays in hippocampal aging: statistical profiling identifies novel processes correlated with cognitive impairment. J. Neurosci., 23, 3807-3819.
9. Bunney, W.E. & Bunney, B.G. (2000) Molecular clock genes in man and lower animals: possible implications for arcadian abnormalities in depression. Neuropsychopharmacology, 22, 335-345.
10. Carter, R.J., Hunt, M.J. & Motion, A.J. (2000) Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington's disease gene. Mov. Disord., 15, 925-937.
11. Carter, R.J., Lione, L.A., Humby, T., Mangiarini, L., Mahal, A., Bates, G.P., Dunnett, S.B. & Morton, A.J. (1999) Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J. Neurosci., 19, 3248-3257.
12. Cepeda, C., Hurst, R.S., Calvert, C.R., Hernandez-Echeagaray, E., Nguyen, O.K., Jocoy, E., Christian, L.J., Ariano, M.A. & Levine, M.S. (2003) Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J. Neurosci., 23, 961-969.
13. Chan, E.Y., Luthi-Carter, R., Strand, A., Solano, S.M., Hanson, S.A., DeJohn, M.M., Kooperberg, C., Chase, K.O., DiFiglia, M., Young, A.B., Leavitt, B.R., Cha, J.H., Aronin, N., Hayden, M.R. & Olson, J.M. (2002) Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. Hum. Mol. Genet., 11, 1939-1951.
14. Dedeoglu, A., Kubilus, J.K., Yang, L., Ferrante, K.L., Hersch, S.M., Beal, M.F. & Ferrante, R.J. (2003) Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J. Neurochem., 85, 1359-1367.
15. Dunnett, S.B., Nathwani, F. & Brasted, P.J. (1999) Medial prefrontal and neostriatal lesions disrupt performance in an operant delayed alternation task in rats. Behav. Brain Res., 106, 13-28.
16. Edwardson, J.M., Wang, C.T., Gong, B., Wyttenbach, A., Bai, J., Jackson, M.B., Chapman, E.R. & Morton, A.J. (2003) Expression of mutant huntingtin blocks exocytosis in PC12 cells by depletion of complexin II. J. Biol. Chem., 278, 30849-30853.
17. Farlow, M. (2002) A clinical overview of cholinesterase inhibitors in Alzheimer's disease. Int. Psychogeriatr., 14 (Suppl. 1), 93-126.
18. Ferrante, R.J., Andreassen, O.A., Jenkins, B.G., Dedeoglu, A., Kuemmerle, S., Kubilus, J.K., Kaddurah-Daouk, R., Hersch, S.M. & Beal, M.F. (2000) Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci., 20, 4389-4397.
19. Finberg, J.P. (1995) Pharmacology of reversible and selective inhibitors of monoamine oxidase type A. Acta Psychiatr. Scand. Supplement, 386, 8-13.
20. Galderisi, S., Mucci, A., Bucci, P., Mignone, M.L. & Maj, M. (1996) Influence of moclobemide on cognitive functions of nine depressed patients: pilot trial with neurophysiological and neuropsychological indices. Neuropsychobiology, 33, 48-54.
21. Giacobini, E. (2000) Cholinesterase inhibitors stabilize Alzheimer's disease. Ann. N. Y. Acad. Sci., 920, 321-327.
22. Hakak, Y., Walker, J.R., Li, C., Wong, W.H., Davis, K.L., Buxbaum, J.D., Haroutunian, V. & Fienberg, A.A. (2001) Genome-wide expression analysis reveals deregulation of mediation-related genes in chronic schizophrenia. Proc. Natl. Acad. Sci. USA, 98, 4746-4751.
23. Hurlbert, M.S., Zhou, W., Wasmeier, C., Kaddis, F.G., Hutton, J.C. & Freed, C.R. (1999) Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. Diabetes, 48, 649-651.
24. Karpuj, M.V., Becher, M.W., Springer, J.E., Chabas, D., Youssef, S., Pedotti, R., Mitchell, D. & Steinman, L. (2002) Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine, Nat. Med., 8, 143-149.
25. Kolb, B., Sutherland, R.J. & Singh, R.K. (1975) Double dissociation of spatial impairments and perseveration following selective prefrontal lesions in rats. J. Comp. Physiol. Psychol., 88, 806-815.
26. Lastres-Becker, I., Hansen, H.H., Berrendero, F., De Miguel, R., Perez-Rosado, A., Manzanares, J., Ramos, J.A. & Fernandez-Ruiz, J. (2002) Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. Synapse, 44, 23-35.
27. Lawrence, A.D., Sahakian, B.J., Hodges, J.R., Rosser, A.E., Lange, K.W. & Robbins, T.W. (1996) Executive and mnemonic functions in early Huntington's disease. Brain, 119, 1633-1645.
28. Lawrence, A.D., Sahakian, B.J., Rogers, R.D., Hodges, J.R. & Robbins, T.W. (1999) Discrimination, reversal, and shift learning in Huntington's disease: mechanisms of impaired response selection. Neuropsychologia, 37, 1359-1374.
29. Lemstra, A.W., Eikelenboom, P. & van Gool, W.A. (2003) The cholinergic deficiency syndrome and its therapeutic implications. Gerontology, 49, 55-60.
30. Lione, L.A., Carter, R.J., Hunt, M.J., Bates, G.P., Morton, A.J. & Dunnett, S.B. (1999) Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J. Neurosci., 19, 10428-10437.
31. Livak, K.J. & Schmittgen, T.D. (2001) Analysis of relative gene expression data using real time quantitative PCR and the 2(T)(-Delta Delta C) method. Methods, 25, 402-408.
32. Luthi-Carter, R., Hanson, S.A., Strand, A.D., Bergstrom, D.A., Chun, W., Peters, N.L., Woods, A.M., Chan, E.Y., Kooperberg, C., Krainc, D., Young, A.B., Tapscott, S.J. & Olson, J.M. (2002a) Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum. Mol. Genet, 11, 1911-1926.
33. Luthi-Carter, R., Strand, A.D., Hanson, S.A., Kooperberg, C., Schilling, G., La Spada, A.R., Merry, D.E., Young, A.B., Ross, C.A., Borchelt, D.R. & Olsen, J.M. (2002b) Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Hum. Mol. Genet., 11, 1927-1937.
34. Luthi-Carter, R., Strand, A., Peters, N.L., Solano, S.M., Hollingsworth, Z.R., Menon, A.S., Frey, A.S., Spektor, B.S., Penney, E.B., Schilling, G., La Spada, A.R., Merry, D.E., Young, A.B., Ross, C.A., Borchelt, D.R. & Olsen, J.M. (2000) Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet., 9, 1259-1271.
35. Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S.W. & Bates, G.P. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell, 87, 493-506.
36. Michikawa, M. (2003) The role of cholesterol in pathogenesis of Alzheimer's disease: dual metabolic interaction between amyloidal beta-protein and cholesterol. Mol. Neurobiol., 21, 1-12.
37. Morton, A.J. & Edwardson, J.M. (2001) Progressive depletion of complexin II in a transgenic mouse model of Huntington's disease. J. Neurochem., 76, 166-172.
38. Morton, A.J., Faull, R.L. & Edwardson, J.M. (2001) Abnormalities in the synaptic vesicle fusion machinery in Huntington's disease. Brain Res. Bull., 56, 111-117.
39. Morton, A.J., Lagan, M.A., Skepper, J.N. & Dunnett, S.B. (2000) Progressive formation of inclusions in the striatum and hippocampus of mice transgenic for the human Huntington's disease mutation. J. Neurocytol., 29, 679-702.
40. Morton, A.J., Wood, N.I., Hastings, M.H., Hurebrink, G., Barker, R.A. & Maywood, E.S. (2005) Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. J. Neurosci., 25, 157-163.
41. Murphy, K.P., Carter, R.J., Lione, L.A., Mangiarini, L., Mahal, A., Bates, G.P., Dunnett, S.B. & Morton, A.J. (2000) Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J. Neurosci., 20, 5115-5123.
42. Orr, H.T. (2002) Microarrays and polyglutamine disorders: Reports from the Hereditary Disease Array Group. Hum. Mol. Genet., 11, 1909-1910.
43. 2+-dependent neurotransmitter release. Cell, 104, 71-81.
44. Ridley, R.M., Clark, B.A., Durnford, L.J. & Baker, H.F. (1993) Stimulus-bound perseveration after frontal ablations in marmosets. Neuroscience, 52, 595-603.
45. Rot, U., Kobal, J., Sever, A., Pirtosek, Z. & Mesec, A. (2002) Rivastigmine in the treatment of Huntington's disease. Eur. J. Neurol., 9, 689-701.
46. Roth, M., Mountjoy, C.Q. & Amrein, R. (1996) Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial. Br. J. Psychiatry, 168, 149-157.
47. Rubinsztein, D.C., Leggo, J., Chiano, M., Dodge, A., Norbury, G., Rosser, E. & Craufurd, D. (1997) Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington disease. Proc. Nat. Acad. Sci. USA, 94, 3872-3876.
48. Sipione, S., Rigamonti, D., Valenza, M., Zuccato, C., Conti, L., Pritchard, J., Kooperberg, C., Olson, J.M. & Cattaneo, E. (2002) Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. Hum. Mol. Genet., 11, 1953-1965.
49. Steur, E.N. & Ballering, L.A. (1997) Moclobemide and selegeline in the treatment of depression in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 63, 547.
50. Sutherland, R.J., Kolb, B. & Whishaw, I.Q. (1982) Spatial mapping: definitive disruption by hippocampal or medial frontal cortical damage in the rat. Neurosci. Lett., 31, 271-276.
51. Tamayo, P., Slonim, D., Mesirov, J., Zhu, Q., Kitareewan, S., Dmitrovsky, E., Lander, E.S. & Golub, T.R. (1999) Interpreting patterns of gene expression with self-organising maps: Methods and application to hematopoietic differentiation. Proc. Nat. Acad. Sci. USA, 96, 2907-2912.
52. The Huntington's Disease Collaborative Research Group. (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell, 72, 971-983.
53. Turmaine, M., Raza, A., Mahal, A., Mangiarini, L., Bates, G.P. & Davies, S.W. (2000) Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc. Natl. Acad. Sci. USA, 97, 8093-80837.
54. Verbessem, P., Lemiere, J., Eindje, B.O., Swirmen, S., Vanhees, L., Leemputte, M., Hespel, P. & Dom, R. (2003) Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial. Neurology, 61, 925-930.
55. Wyss, M. & Kaddurah-Daouk, R. (2000) Creatine and creatinine metabolism. Physiol. Rev., 80, 1107-1213.